CTRI/2013/06/003780
Completed
未知
An open label, monocentric, pilot study to evaluate the safety and efficacy of anti ageing product in healthy adult female subjects with skin type III to V. - NI
Sami Labs P Ltd0 sites12 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Sami Labs P Ltd
- Enrollment
- 12
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Female adult subjects in general good health as determined from
- •a recent medical history.
- •2\. Subjects in the age group of 30 \- 50 years (both ages inclusive).
- •3\. Subjects with Fitzpatrickâ??s skin types III, IV, and V.
- •4\. Subjects having visible fine lines and wrinkles, i.e,
- •Glabellar frownlines/Crowâ??s feet/nasolabial folds/forehead lines
- •and perioral wrinkles or few or all of them.
- •5\. Subjects who have not under gone any facial anti ageing
- •procedures (e.g. Botulinum toxin, dermal filler injections, laser
- •resurfacing) in the past 1 year.
Exclusion Criteria
- •1\.A known history or present condition of allergic
- •response/hypersensitivity to any cosmetic ingredients,pharmaceutical products or any ingredient of the IP.
- •2\. Female subjects with positive pregnancy test or not practicing contraception and nursing mothers.
- •3\. History of intense sun exposure.
- •4\. Presence of any underlying, clinically significant uncontrolled medical illness.
- •5\. Subject having active skin diseases
- •6\. Subject participating in any other cosmetic or therapeutic study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A pilot study to assess the efficacy and safety of CBD oral solution in addition to standard treatment for pediatric subjects with Developmental and Epileptic EncephalopathyDevelopmental and Epileptic Encephalopathy (DEE)MedDRA version: 20.0Level: PTClassification code 10077380Term: Epileptic encephalopathySystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2019-001633-14-ITIRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA20
Recruiting
Phase 1
Pentosan Polysulfate Sodium (PPS) in subjects with mucopolysaccharidosis type I (MPS I)Mucopolysaccharidosis type I (MPS I)Metabolic and Endocrine - Metabolic disordersHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12620000823976Paradigm Biopharmaceuticals Pty Ltd10
Not yet recruiting
Not Applicable
A prospective study to assess the effect of adalimumab on cardiovascular biomarkers in participants with severe chronic plaque psoriasisChronic plaque psoriasisSkin - Dermatological conditionsInflammatory and Immune System - Other inflammatory or immune system disordersACTRN12613000419763Dr Anna Braue15
Recruiting
Phase 2
Study to evaluate the efficacy of Sucralfate as a healing agent in bed sores.CTRI/2016/03/006745Internal FLUID Grant Christian Medical College Vellore30
Withdrawn
Phase 1
A SINGLE CENTER OPEN-LABEL PILOT STUDY TO EVALUATE THE TOLERABILITY AND SAFETY OF A SYNTHETIC SOFT TISSUE IMPLANT MATERIAL IN THE SKIN OF NORMAL VOLUNTEERSTolerability and safety of a new synthetic soft tissue implant material for soft tissue augmentation in healthy volunteers.Surgery - Other surgeryACTRN12607000223437COSMETREND PTY LTD8